Non-transfusion-dependent thalassemia encompasses three clinically distinct forms -- beta-thalassaemia intermedia, hemoglobin E/beta-thalassaemia (mild and moderate forms), and al ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

DKMS Foundation India inaugurates new BMT unit in Ahmedabad, providing hope and treatment for thalassemia patients in Gujarat ...

Tharu tribals face higher rates of thalassemia (22-24%) and sickle cell anaemia (60%) than the general population, prompting a medical camp for 2 lakh people.

An estimated 12,000 children are born with thalassemia major, a severe form of the disease, in India each year, accounting ...

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

A Thalassemia screening desk has been inaugurated at the NADRA centre in Sukkur on Saturday marking a significant step ...

Commissioner Sargodha Division Jahanzeb Awan visited the Thalassemia and Hemophilia Centre at Hilal-e-Ahmer Hospital to review the ...

Bone marrow transplantation is a costly procedure. Depending on the type of transplant the rate may vary from ₹7 lakh to ₹50 ...

A Thalassemia screening desk has been inaugurated at the NADRA center in Sukkur on Saturday marking a significant step ...

As India remains the thalassemia capital of the world, the Thalassemia Patients Advocacy Group (TPAG) has written an open ...

Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and ...